Clinical effect of magnesium isoglycyrrhizinate on moderate and severe nonalcoholic steatohepatitis and its mechanism analyse

Objective To observe the clinical effect of magnesium isoglycyrrhizinate on moderate and severe nonalcoholic steatohepatitis(NASH) and analyse its mechanism. Methods 42 cases with moderate and severe nonalcoholic steatohepatitis were included in our study. All patients were divided into observation group and control group randomly. Control group were received simvastatin while the observation group were received simvastatin combined with magnesium isoglycyrrhizinate treatment. The course was 6 weeks.The changes of NASH classification, clinical symptom, liver function, lipid levels and liver fibrosis items in two groups before and after treatment were observed and recorded. Results All patients were received 6 week treatment, none of them dropped out. The clinical symptoms were improved in both two groups. There were 5 severe NASH improved to moderate NASH, 8 moderate NASH improved to mild NASH in observation group while only 3 severe NASH improved to moderate NASH in control group. The difference of NASH classification between two groups was significant(P0.05). Compared to pre-treatment, the AST, ALT, TBIL, γ-GT were decreased in both two groups. But the liver function items in observation were lower than control group(P0.05). The lipid level were decreased in both two group and there were no significant differences between two groups after treatment. The level of PC III, HA, C-IV were decreased in observation group while had no changes in control group. Conclusion The magnesium isoglycyrrhizinate could decrease the AST, ALT and lipid level, improve the classification of liver fibrosis, and had low rate of side effect during treatment.